Qynapse releases new data demonstrating the value of QyScore® for the clinical assessment of Multiple Sclerosis (MS)

These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.

Qynapse sponsors the 8th joint ACTRIMS-ECTRIMS meeting – MSVirtual2020

Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.

Qynapse supports the investigation of Covid-19 neurological manifestations

Qynapse is developing collaborations with European and US hospitals to support the diagnosis and monitoring of neurological complications of the virus, by providing QyScore® to automatically quantify brain MRI markers in COVID-19 patients for retrospective or prospective analyses.

Qynapse releases new validation results on QyScore® performance during AAIC 2020 Conference

QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting

Qynapse is pleased to participate in the 2020 Alzheimer’s Association International Conference virtual event

Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.

Qynapse receives FDA clearance for QyScore®, a novel imaging software for central nervous system diseases

QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders